RxDoctor Payments Data

Mary Knesevich

Psychiatry · Dallas, TXNPI 1033120811

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (53.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 54.9% of the total. Reporting peaked in 2020 at $1,890 and has fallen 94.3% since, to $108 in 2023.

$3,568in general payments, 2019–2025

Across 6 payments — averaging $594.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$2K
  • Roche TCRC, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$39
$1,721,869in research payments, 2019–2025

Across 247 payments — averaging $6971.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$314K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$257K
  • Boehringer Ingelheim$254K
  • Teva Pharmaceuticals USA, Inc.$229K
  • Bioxcel Therapeutics, Inc.$165K
  • Roche TCRC, Inc.$143K
  • plus $359K from 9 others

What the payments were for

  • Consulting fees$1,89053%
  • Travel & lodging$1,14632%
  • Food & beverage$53215%

General payments by program year

20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,568 in reported general payments places this provider in the 80th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Other psychiatry in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →